Education

1984       Graduation, Kurfürst-Friedrich Gymnasium, Heidelberg, DE.

1992       MD degree, Univ. Heidelberg, Munich, Hannover, DE.

1994       MD degree USA, ECFMG certificate.

2007       DMSc, Rigshospitalet, Univ. of CPH, DK.

2017       Board certified specialist Internal Medicine & Hematology, DK+SE.

Career

Since 2018

Combined clinical and research position: Senior Consultant, Dept. pf Hematology, Rigshospitalet, Group Leader and Associate Prof., Finsen Laboratory, Rigshospitalet, Biotech Research and Innovation Centre, Program for Translational Hematology, DanStem, NNF Center for Stem Cell Research Univ. of CPH, DK.

2008-2017

Combined clinical and research position: Since 2013 50% Group Leader and Associate Prof., Finsen Laboratory, Rigshospitalet & Biotech Research and Innovation Centre, Univ. of CPH, DK (Novo Nordisk clinical research scholarship 2013-2017), 50% Clinician, Dept. of Hematology, Univ. of Lund, SE.

2005-2007       

Post.doc., Laboratory for Gene Therapy Research, Rigshospitalet, University of Copenhagen, Denmark.

1998-2004       

DMSc research fellow, The Granulocyte Research Laboratory, Dept. of Hematology, Rigshospitalet, University of Copenhagen.

1992 -1998      
Clinician, Dept.  of Hematology-Oncology (24 month), University of Heidelberg, DE. Dept. of Clinical Immunology (21 month) and Dept. of Hematology (12 month), Rigshospitalet, University of CPH, DK.

Acute Myeloid Leukemia – Leukemic Stem Cells and Clinical Trials

Hematopoietic stem cells

Identification and therapeutic targeting of "oncogenic" signaling and DNA damage response pathways in preclinical models of human AML.

Novel antibody-drug conjugate therapy targeting leukemic stems cells in AML patients.

Sponsoring PI of translational exploratory investigator-initiated AML trial in collaboration with 14 Nordic AML centers. Our trial conducts extensive AML profiling including genomics, transcriptomics, phosphoproteomics, and ex vivo drug screening to identify novel effective drug combinations targeting therapy-resistant minimal residual disease/leukemic stem cells in AML patients.

Application of our novel human hematopoietic stem cell markers for (i) refinement of the human HSC phenotype and (ii) production of highly purified stem cell grafts applicable for autologous stem cell transplantation of AML and other cancer patients, as well as gene therapy of patients with monogenic diseases.

Acute Myeloid Leukemia – therapeutic targeting of leukemic stem cells

Translational exploratory investigator-initiated AML trials in collaboration with the Nordic AML Group

Hematopoietic stem cells - biology and clinical application

Normal and malignant hematopoietic/myeloid development